Migita Kiyoshi, Abiru Seigo, Maeda Yumi, Daikoku Manabu, Ohata Kazuyuki, Nakamura Minoru, Komori Atsumasa, Yano Koji, Yatsuhashi Hiroshi, Eguchi Katsumi, Ishibashi Hiromi
Clinical Research Center, NHO Nagasaki Medical Center, and Department of Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Kubara 2-1001-1, Omura, Nagasaki 856-8562, Japan.
Hum Immunol. 2006 Jan-Feb;67(1-2):27-32. doi: 10.1016/j.humimm.2006.02.025. Epub 2006 Mar 31.
Interleukin-6 (IL-6) is an important cytokine in liver regeneration, and elevated levels of IL-6 have been demonstrated in patients with chronic liver diseases (CLD). Many biological effects of IL-6 depend on naturally occurring soluble IL-6 receptors. In the present study we measured the concentrations of IL-6 and its soluble receptors in the sera of patients with CLD related to hepatitis C virus (HCV) infection. We studied 77 patients with varying degrees of HCV-related CLD. Serum levels of IL-6 and its soluble receptors (sIL-6R, sgp130) were measured by enzyme-linked immunosorbent assay. Serum IL-6 and sIL-6R were elevated in patients with CLD compared with healthy subjects. Serum levels of sgp130 did not differ between patients with chronic hepatitis and healthy subjects. However, in patients with liver cirrhosis, sgp130 was significantly elevated and was positively correlated with total bilirubin and negatively correlated with cholinesterase and prothrombin time. Our study demonstrated that in patients with HCV-related CLD, serum IL-6 and its soluble receptor levels are correlated with both liver function impairment and the degree of liver fibrosis. These observations suggest that the balance of IL-6 and its soluble receptors may correspond to the state of liver damage in patients with CLD.
白细胞介素-6(IL-6)是肝脏再生中的一种重要细胞因子,慢性肝病(CLD)患者体内已证实IL-6水平升高。IL-6的许多生物学效应依赖于天然存在的可溶性IL-6受体。在本研究中,我们测定了丙型肝炎病毒(HCV)感染相关CLD患者血清中IL-6及其可溶性受体的浓度。我们研究了77例不同程度HCV相关CLD患者。采用酶联免疫吸附测定法检测血清IL-6及其可溶性受体(sIL-6R、sgp130)水平。与健康受试者相比,CLD患者血清IL-6和sIL-6R升高。慢性肝炎患者与健康受试者的血清sgp130水平无差异。然而,肝硬化患者的sgp130显著升高,且与总胆红素呈正相关,与胆碱酯酶和凝血酶原时间呈负相关。我们的研究表明,在HCV相关CLD患者中,血清IL-6及其可溶性受体水平与肝功能损害和肝纤维化程度均相关。这些观察结果提示,IL-6及其可溶性受体的平衡可能与CLD患者的肝损伤状态相对应。